![](https://investorshub.advfn.com/uicon/434772.png?cb=1479377918)
Wednesday, March 14, 2018 11:08:57 AM
Here is an extract of the article:
Neuroderm Chief Scientist Officer Dr. Oron Yacoby-Zeevi may seem rather unassuming when compared to some of the other game-changers on this list, but there’s a very good reason she joins the other nine candidates. Israel’s Neuroderm, a clinical-stage pharmaceutical firm developing next-generation treatments for disorders of the central nervous system, was sold to Mitsubishi Tanabe Pharma for $1.1 billion in what is said to be Israel’s largest Pharma exit earlier this year. Yacoby-Zeevi, according to a report in Globes, had a hand in that exit, at least in part, because she is responsible for the company’s technological solution. NeuroDerm has developed a liquid version of a drug already in existence to treat Parkinson’s Disease. This groundbreaking achievement will certainly improve the lives of patients around the world who suffer from the disease, while also generating profits for the company
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM